Analysis
Electra Therapeutics priced its upsized IPO at $15 per share, selling 23,333,334 shares for roughly $350 million, then closed its first day of Nasdaq trading under ticker ETRA down nearly 12% at $13.25, according to Cooley and EBC Financial Group.
What Changed Since Pulse's Last Coverage
Pulse previously covered Electra's IPO terms the week before pricing, alongside Holtec Nuclear and Bamboo Insurance in the same fall IPO cohort. Since then, Electra has actually priced and completed its debut -- the first of that trio to do so -- giving the first real trading data point on how this week's IPO class performs once shares are freely tradable rather than just filed or roadshowed.
“## A Rockier Debut Than Recent Peers Electra's stock was indicated to open around $16.25, above its $15 offer price, suggesting genuine early demand.”
A Rockier Debut Than Recent Peers
Electra's stock was indicated to open around $16.25, above its $15 offer price, suggesting genuine early demand. But it closed the day at $13.25, down nearly 12% from where it priced. That is a meaningfully different outcome than several other biotech debuts this quarter: Parabilis Medicines priced its own IPO above range at $20 and opened up 66.75%, while BillionToOne jumped 66.67% on its Nasdaq debut. Electra's decline breaks what had been read as a consistent run of strong first-day pops evidencing a fully reopened biotech IPO window.
Company Background
Founded in 2018 and headquartered in South San Francisco, Electra Therapeutics has roughly 46 employees. Prior funding rounds before this IPO:
- Series B (2022) -- $84 million.
- Series C (2025) -- $183 million.
- Total raised pre-IPO -- approximately $401.2 million.
Its lead program, ELA026, targets signal regulatory proteins (SIRP) and is in Phase 1 development for secondary hemophagocytic lymphohistiocytosis, a fatal hyperinflammatory condition -- an earlier-stage, single-indication pipeline compared to some peers that priced more successfully this cycle. Jefferies, TD Cowen, Evercore ISI and Cantor Fitzgerald served as joint bookrunners.
The Numbers In Context
A $350 million raise closing down 12% on day one is not a failed IPO by any conventional measure -- the company still banked its target capital -- but it is a clear underperformance relative to Parabilis and BillionToOne's pops in the same broader window, and it complicates the narrative that the biotech IPO window is uniformly strong right now. Pricing at the midpoint and then trading down suggests either the offer price was set too aggressively relative to actual investor demand, or broader risk appetite for early-stage, single-indication biotechs softened between roadshow and pricing.
What To Watch
Whether Electra's stock stabilizes above or continues sliding below its $13.25 close in the coming weeks will show whether day-one selling reflected temporary IPO-allocation flipping or a genuine repricing of the company's risk profile. For the two other companies in Pulse's original trio -- Holtec Nuclear and Bamboo Insurance -- Electra's outcome is now a direct data point on how much appetite public markets currently have for pre-revenue, single-asset biotech stories specifically, separate from the broader IPO market's health.